Clinical Trial

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-04-18; most recent amendment 2026-01-27.
Status change: Terminated → Active, Not Recruiting 2026-01-27
Status change: Recruiting → Terminated 2025-08-01
Status change: Not Yet Recruiting → Recruiting 2023-01-31
Trial Details
NCT Number NCT05340309
Lead Sponsor University of Southern California
Collaborators: National Cancer Institute (NCI), Genentech, Inc.
Conditions Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 +3 more
Enrollment 5 participants
Start Date 2022-12-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-29